Triacetyluridine (TAU) Decreases Depressive Symptoms and Increases Brain pH in Bipolar Patients

Experimental and Clinical Psychopharmacology

Volumn 16, Issue 3, 2008, Pages 199-206

  Jensen, J Eric ^a,b   Daniels, Melissa ^a   Haws, Charlotte ^a   Bolo, Nicolas R ^a,b   Lyoo, In Kyoon ^c   Yoon, Sujung J ^d   Cohen, Bruce M ^a,b   Stoll, Andrew L ^a,b   Rusche, James R ^e   Renshaw, Perry F ^a,b  

^a MCLEAN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Seoul National University College of Medicine   (South Korea)

^d The Catholic University of Korea   (South Korea)

^e REPLIGEN CORPORATION   (United States)

Author keywords

bipolar disorder; brain; hydrogen ion concentration (pH); phosphorus magnetic resonance spectroscopy (31P MRS); triacetyluridine (TAU)

Indexed keywords

AMITRIPTYLINE; AMPHETAMINE; CLONAZEPAM; FLUVOXAMINE; GABAPENTIN; GEMFIBROZIL; LAMOTRIGINE; LEVOTHYROXINE SODIUM; LORATADINE; LORAZEPAM; MESALAZINE; METHYLPHENIDATE; MIRTAZAPINE; OLANZAPINE; PRAVASTATIN; QUAZEPAM; QUETIAPINE; TRAZODONE; TRIACETYLURIDINE; URIDINE DERIVATIVE; VALPROATE SEMISODIUM; VENLAFAXINE; ZOLPIDEM;

ADULT; ARTICLE; BIOENERGY; BIPOLAR DEPRESSION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG MECHANISM; FEMALE; HUMAN; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PH MEASUREMENT; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; BRAIN CHEMISTRY; DEPRESSIVE DISORDER; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MITOCHONDRIA; NEUROPSYCHOLOGICAL TESTS; PHOSPHOCREATINE; PSYCHIATRIC STATUS RATING SCALES; URIDINE;

EID: 44949161985     PISSN: 10641297     EISSN: None     Source Type: Journal    
DOI: 10.1037/1064-1297.16.3.199     Document Type: Article

References (37)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision (2000), Author, Washington, DC
2. Asberg M., Montgomery S.A., Perris C., Schalling D., and Sedvall G. A comprehensive psychopathological rating scale. Acta Psychiatrica Scandinavica Supplementum 271 (1978) 5-28
3. Ashour O.M., Naquib F.N., and el Kouni M.H. 5-(m-Benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2′,3′,5′-tri-O-acetyluridine, a prodrug of uridine, as modulators of plasma uridine concentration. Implications for chemotherapy. Biochemical Pharmacology 51 (1996) 1601-1611
4. Brambilla P., Stanley J.A., Nicoletti M.A., Sassi R.B., Mallinger A.G., Frank E., et al. 1H magnetic resonance spectroscopy investigation of the dorsolateral prefrontal cortex in bipolar disorder patients. Journal of Affective Disorders 86 (2005) 61-67
5. Brambilla P., Stanley J.A., Sassi R.B., Nicoletti M.A., Mallinger A.G., Keshavan M.S., et al. 1H MRS study of dorsolateral prefrontal cortex in healthy individuals before and after lithium administration. Neuropsychopharmacology 29 (2004) 1918-1924
6. Crossley N.A., and Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: Two meta-analyses of randomized, placebo-controlled trials. Journal of Clinical Psychiatry 68 (2007) 935-940
7. Dager S.R., Friedman S.D., Parow A., Demopulos C., Stoll A.L., Lyoo I.K., et al. Brain metabolic alterations in medication-free patients with bipolar disorder. Archives of General Psychiatry 61 (2004) 450-458
8. Deicken R.F., Fein G., and Weiner M.W. Abnormal frontal lobe phosphorous metabolism in bipolar disorder. American Journal of Psychiatry 152 (1995) 915-918
9. Deicken R.F., Peques M.P., Anzalone S., Feiwell R., and Soher B. Lower concentration of hippocampal N-acetylaspartate in familial bipolar I disorder. The American Journal of Psychiatry 160 (2003) 873-882
10. Dube S., Tollefson G.D., Thase M.E., Briggs S.D., Van Campen L.E., Case M., et al. Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. Bipolar Disorder 9 (2007) 618-627
11. Erecinska M., and Silver I.A. ATP and brain function. Journal of Cerebral Blood Flow and Metabolism 9 (1989) 2-19
12. Ghaemi S.N., Gilmer W.S., Goldberg J.F., Zablotsky B., Kemp D.E., Kelley M.E., et al. Divalproex in the treatment of acute bipolar depression: A preliminary double-blind, randomized, placebo-controlled pilot study. Journal of Clinical Psychiatry 68 (2007) 1840-1844
13. Hamakawa H., Murashita J., Yamada N., Inubushi T., Kato N., and Kato T. Reduced intracellular pH in the basal ganglia and whole brain measured by 31P-MRS in bipolar disorder. Psychiatry and Clinical Neurosciences 58 (2004) 82-88
14. Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 32 (1959) 50-55
15. Iotti S., Frassineti C., Alderighi L., Sabatini A., Vacca A., and Barbiroli B. In vivo assessment of free magnesium concentration in human brain by 31P MRS. A new calibration curve based on a mathematical algorithm. NMR in Biomedicine 9 (1996) 24-32
16. Iotti S., Frassineti C., Sabatini A., Vacca A., and Barbiroli B. Quantitative mathematical expressions for accurate in vivo assessment of cytosolic ADP and DeltaG of ATP hydrolysis in the human brain and skeletal muscle. Biochimica et Biophysica Acta 1708 (2005) 164-177
17. Jenkins B.G., Klivenyi P., Kustermann E., Andreassen O.A., Ferrante R.J., Rosen B.R., et al. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increase in glutamine and glucose in transgenic Huntington's disease mice. Journal of Neurochemistry 74 (2000) 2108-2119
18. Jensen J.E., Drost D.J., Menon R.S., and Williamson P.C. In vivo brain (31)P-MRS: Measuring the phospholipid resonances at 4 Tesla from small voxels. NMR in Biomedicine 15 (2002) 338-347
19. Kato T., and Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disorders 2 (2000) 180-190
20. Kato T., Takahashi S., Shioiri T., and Inubushi T. Brain phosphorous metabolism in depressive disorders detected by phosphorus-31 magnetic resonance spectroscopy. Journal of Affective Disorders 26 (1992) 223-230
21. Kato T., Takahashi S., Shioiri T., and Inubushi T. Alterations in brain phosphorous metabolism in bipolar disorder detected by in vivo 31P and 7Li magnetic resonance spectroscopy. Journal of Affective Disorders 27 (1993) 53-59
22. Kato T., Takahashi S., Shioiri T., Murashita J., Hamakawa H., and Inubushi T. Reduction of brain phosphocreatine in bipolar II disorder detected by phosphorus-31 magnetic resonance spectroscopy. Journal of Affective Disorders 31 (1994) 125-133
23. Kemp G.J., and Radda G.K. Quantitative interpretation of bioenergetic data from 31P and 1H magnetic resonance spectroscopic studies of skeletal muscle: An analytical review. Magnetic Resonance Quarterly 10 (1994) 43-63
24. Leahy R.L. Bipolar disorder: Causes, contexts, and treatments. Journal of Clinical Psychology 63 (2007) 417-424
25. Lehninger A.L., Nelson D.L., and Cox M.M. Principles of biochemistry. 2nd ed. (1993), Worth, New York
26. Merikangas K.R., Chakravarti A., Moldin S.O., Araj H., Blangero J.C., Burmeister M., et al. Future of genetics of mood disorders research. Biological Psychiatry 52 (2002) 457-477
27. Moffett J.R., and Namboodiri M.A. Differential distribution of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat forebrain. Journal of Neurocytology 24 (1995) 409-433
28. Moore G.J., Bebchuk J.M., Hasanat K., Chen G., Seraji-Bozorgzad N., Wilds I.B., et al. Lithium increases N-acetyl-aspartate in the human brain: In Vivo evidence in support of bcl-2's neurotropic effects?. Biological Psychiatry 48 (2000) 1-8
29. Naviaux, R. K. (2000, March). Pyrimidine therapy of mitochondrial disease. Mitochondria: Interaction of two genomes. In Second NIH mitochondria minisymposium. Symposium conducted as part of the NIH Director's Wednesday Afternoon Lecture Series Event, Bethesda, MD.
30. Ohara K., Isoda H., Suzuki Y., Takehara Y., Ochiai M., Takeada H., et al. Proton magnetic resonance spectroscopy of the lenticular nuclei in bipolar I affective disorder. Psychiatry Research 84 (1998) 55-60
31. Petroff O.A., Errante L.D., Rothman D.L., Kim J.H., and Spencer D.D. Neuronal and glial metabolite content of the epileptogenic human hippocampus. Annals of Neurology 52 (2002) 635-642
32. Santos J.N., Hempstead K.W., Kopp L.E., and Miech R.P. Nucleotide metabolism in rat brain. Journal of Neurochemistry 15 (1968) 367-376
33. Sharma R., Venkatasubramanian P.N., Barany M., and Davis J.M. Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients. Schizophrenia Research 8 (1992) 43-49
34. Silverstone P.H., Wu R.H., O'Donnell T., Ulrich M., Asqhar S.J., and Hanstock C.C. Chronic treatment with lithium, but not sodium valproate, increases cortical N-acetyl-aspartate concentrations in euthymic bipolar patients. International Clinical Psychopharmacology 18 (2003) 73-79
35. Stork C., and Renshaw P.F. Mitochondrial dysfunction in bipolar disorder: Evidence from magnetic resonance spectroscopy research. Molecular Psychiatry 10 (2005) 900-919
36. Urenjak J., Williams S.R., Gadian D.G., and Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. The Journal of Neuroscience 13 (1993) 981-989
37. Young R.C., Biggs J.T., Ziegler V.E., and Meyer D.A. A rating scale for mania: Reliability, validity and sensitivity. The British Journal of Psychiatry 133 (1978) 429-435